Immunotherapy in head and neck cancer: Harnessing profit on a system disruption

被引：6
作者：
Rancoule, Chloe [1 ]
Vallard, Alexis [1 ]
Espenel, Sophie [1 ]
Guy, Jean-Baptiste [1 ,2 ]
Xia, Yaoxiong [1 ]
Hamrouni, Anis El Meddeb [1 ]
Rodriguez-Lafrasse, Claire [2 ,3 ]
Chargari, Cyrus [4 ,5 ,6 ]
Deutsch, Eric [4 ]
Magne, Nicolas [1 ,2 ]
机构：
[1] Lucien Neuwirth Canc Inst, Dept Radiotherapy, 108 Bis,Ave Albert Raimond,BP 60008, F-42270 St Priest En Jarez, France
[2] Lyon Med Univ, Radiobiol Lab, Lyon, France
[3] Lyon Hosp, Hosp Civils de Lyon, Lyon, France
[4] Grand Paris, Gustave Roussy Campus Canc, Dept Radiotherapy, Paris, France
[5] Grand Paris, Gustave Roussy Campus Canc, INSERM 1030, Mol Radiotherapy, Paris, France
[6] Inst Rech Biomed Armees, Paris, France
来源：
ORAL ONCOLOGY | 2016年 / 62卷
关键词：
SCCHN; Immune system; Immunotherapy; Monoclonal antibodies; Clinical trials; Treatment combination; SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; COMBINING TARGETED THERAPY; HPV-ASSOCIATED HEAD; PHASE-II TRIAL; HUMAN-PAPILLOMAVIRUS; RADIATION-THERAPY; STEM-CELLS; MONOCLONAL-ANTIBODIES; ANTICANCER THERAPY;
D O I：
10.1016/j.oraloncology.2016.09.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune system deregulation and evasion play a key role in cancers' evolution and progression, including squamous cell carcinoma of the head and neck (SCCHN). Development of basic research proposed a whole new vision of cancer treatment, based on a strong biological rational, and targeting intrinsic deregulations. Immunotherapies provide an encouraging strategy for patients' improved outcomes. Immune-based therapies could act on cancer growth and/or development throughout many pathways. If cetuximab is for now the only monoclonal antibody approved for SCCHN management, other strategies, e.g. immune checkpoints openers, are arousing enthusiasm. Clinical trials are multiplying in patients with recurrent/metastatic SCCHN and primary results offer promising outcomes. Prospects of combining various immunotherapies with more established treatments, such as chemotherapy and radiotherapy, seem very encouraging and could provide synergistic benefits. Ongoing phase III clinical trials should soon enlighten us on the next "standard of care" for SCCHN. In the present review we summarized the different immunotherapy strategies that are currently under clinical investigation for SCCHN' medical care. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：153 / 162
页数：10
相关论文
共 50 条
[31]   The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer [J].
Pharaon, Rebecca R. ;
Xing, Yan ;
Agulnik, Mark ;
Villaflor, Victoria M. .
FRONTIERS IN ONCOLOGY, 2021, 11
[32]   Targeting angiogenesis in head and neck cancer [J].
Vassilakopoulou, Maria ;
Psyrri, Amanda ;
Argiris, Athanassios .
ORAL ONCOLOGY, 2015, 51 (05) :409-415
[33]   Immunotherapy Approaches in HPV-Associated Head and Neck Cancer [J].
Julian, Ricklie ;
Savani, Malvi ;
Bauman, Julie E. .
CANCERS, 2021, 13 (23)
[34]   Immunotherapy for head and neck cancer [J].
Wu, Annie A. ;
Niparko, Kevin J. ;
Pai, Sara I. .
JOURNAL OF BIOMEDICAL SCIENCE, 2008, 15 (03) :275-289
[35]   Patient-reported outcomes in immunotherapy for head and neck cancer [J].
Kirtane, Kedar ;
Hoogland, Aasha I. ;
Li, Xiaoyin ;
Rodriguez, Yvelise ;
Scheel, Kelsey ;
Small, Brent J. ;
Oswald, Laura B. ;
Muzaffar, Jameel ;
Kish, Julie A. ;
Bonomi, Marcelo ;
Bhateja, Priyanka ;
Saba, Nabil F. ;
Steuer, Conor E. ;
Chung, Christine H. ;
Jim, Heather S. L. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (07) :1761-1771
[36]   Immunotherapy for head and neck cancer [J].
Szczepanski, Miroslaw J. ;
Whiteside, Theresa L. .
POSTEPY W CHIRURGII GLOWY I SZYI-ADVANCES IN HEAD AND NECK SURGERY, 2009, 8 (03) :45-55
[37]   Immunotherapy in head and neck cancers [J].
Reverdy, Thibaut ;
Gau, Max ;
Karabajakian, Andy ;
Neidhardt, Eve-Marie ;
Fayette, Jerome .
BULLETIN DU CANCER, 2018, 105 :S35-S42
[38]   Head and neck cancer [J].
Mody, Mayur D. ;
Rocco, James W. ;
Yom, Sue S. ;
Haddad, Robert, I ;
Saba, Nabil F. .
LANCET, 2021, 398 (10318) :2289-2299
[39]   Immunotherapy for recurrent/metastatic head and neck cancer [J].
Alfieri, Salvatore ;
Cavalieri, Stefano ;
Licitra, Lisa .
CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2018, 26 (02) :152-156
[40]   Advances and challenges in immunotherapy in head and neck cancer [J].
Aboaid, Hazem ;
Khalid, Taimur ;
Hussain, Abbas ;
Myat, Yin Mon ;
Nanda, Rishi Kumar ;
Srinivasmurthy, Ramaditya ;
Nguyen, Kevin ;
Jones, Daniel Thomas ;
Bigcas, Jo-Lawrence ;
Thein, Kyaw Zin .
FRONTIERS IN IMMUNOLOGY, 2025, 16
12345